Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Culture

25 Aug 2023

Harm Reduction at Psychedelic Gatherings: Best Practices and Strategies

Harm reduction measures and other safety strategies are crucial for positive and responsible experiences. We take a closer look....

By Microdose

Culture

24 Aug 2023

Breaking Down Barriers: Creating Inclusive Psychedelic Communities

Exploring challenges and strategies to increase accessibility and diversity in the psychedelic therapy space....

By Microdose

Health & Wellness

23 Aug 2023

Psychedelics and Addiction: How Substances Like Ibogaine Are Revolutionizing Treatment Options

Addiction is a challenging condition that affects millions of individuals worldwide. Substances like Ibogaine can facilitate profound healing and recovery....

By Microdose
psychedelic mushrooms

Culture

22 Aug 2023

The Intersection of Psychedelic Culture, the Environment, and Sustainability

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Health & Wellness

18 Aug 2023

Microdosing for Longevity: A Tool for Healthy Aging?

A look at the research on microdosing psychedelics and how it may help mental health and longevity....

By Microdose

Culture

17 Aug 2023

Breaking the Stigma: How Psychedelic Advocacy is Changing Public Perception

Advocates are working to educate the public on the benefits of psychedelics, helping to dispel myths and increase access....

By Microdose

Culture

16 Aug 2023

Beyond the Trip: Nurturing a Healthy Psychedelic Lifestyle

We explore the aspects of a holistic psychedelic lifestyle, including integration work, ongoing education, self-care, and community involvement....

By Microdose

Culture

15 Aug 2023

Psychedelic Tourism: A Look at Ethics, Sustainability, and Safety

Exploring psychedelic tourism, with a focus on ethical considerations, sustainability, and strategies to ensure safety and respect for indigenous practices....

By Microdose

Finance

15 Aug 2023

Cybin Reports Q1 Financial Results and Business Highlights

Cybin reports first quarter financial results and business highlights, including updates on key trials....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.